Sanofi purchase for $ $11.6 billion Bioverativ biopharmaceutical

French drugmaker Sanofi reported on Monday (22) that struck a deal to acquire the Bioverativ, an American biopharmaceutical that specializes in treatments against Hemophilia and blood diseases, for $ $105 a share, making the offer totaling $ $11.6 billion. The proposal was approved by the Board of Directors of Bioverativ.
The value offered by papers represents a 64% premium compared to the price at which they closed the trading session on Friday (19). Sanofi plans to finance the purchase through own resources and issuing debt. She estimates that the purchase will have positive effects on the results of 2018 and 2019.
"With the Bioverativ, a leader in the growing market for hemophilia, Sanofi strengthens your presence in the area of specialized care and your leadership on the rare diseases, in line with the action plan to 2020, and creates a platform for growth in other rare diseases of the blood" says, in a statement, the Chief Executive of Sanofi, Olivier Brandicourt.
The company will begin to acquire the shares in February. Its completion will depend on Sanofi to get most of the shares of Bioverativ.